Back to Results
First PageMeta Content
Anatomy / Biology / Ribbon symbolism / Cancer vaccine / Vaccination / Breast cancer / Cancer immunotherapy / Monoclonal antibodies / Metastatic breast cancer / Medicine / Immune system / Immunology


For personal use only ASX: IMU! An Immuno-oncology Company Developing HER-2+ Gastric and Breast Cancer Therapies
Add to Reading List

Document Date: 2015-02-11 19:45:34

Open Document

File Size: 2,97 MB

Share Result on Facebook

City

Los Angeles / Melbourne / London / Sydney / /

Company

GlaxoSmithKline / Novartis / Alchemia / Imugene Limited / Cappello Capital Corp / Biolife! / Bristol-Myers Squibb / /

Continent

Europe / /

Country

United States / Australia / /

Currency

pence / USD / /

Event

M&A / FDA Phase / /

Facility

University of Vienna / /

IndustryTerm

Breast Cancer Therapies / corporate finance / biotechnology / financial services management / investment bank / trial protocol / mass communication media / biotechnology sector / /

MedicalCondition

cancer / metastatic breast cancer / Europe's leading cancer / breast cancer / Endocrine dependent disease / /

MedicalTreatment

immunotherapies / oncology therapy / immunotherapy / /

Organization

University of Vienna / FDA / /

Person

Paul Hopper / Charles Walker / Nick Ede / Consegna / Otto Buttula / Axel Hoos / /

Position

CTO / advisor / CEO / CEO and CFO / Head of Manufacturing / Principal Investigator / Executive Chairman / Vice President / VP Chemistry Chiron / Co-Director / regulatory consultant / specialist corporate finance / Vice President Oncology R&D / Head / COO / Non-Executive Director / /

Product

Herceptin / Herceptin! 04 / 2H2014 / /

PublishedMedium

Milestones / /

Technology

antibodies / biotechnology / trial protocol / /

SocialTag